This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Téllez, N. Articles by Montalban, X. Search for Related Content PubMed PubMed Citation Articles by Téllez, N. Articles by Montalban, X. Social Bookmarking                   What's this?

Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain, ntellez{at}vhebron.net

Manuel Comabella

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain

E va Julià

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain

Jordi Río

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain

M ar Tintoré

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain

Luís Brieva

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain

Carlos Nos

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain

Xavier Montalban

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain

Background and objective Fatigue is one of the most limiting symptoms in multiple sclerosis (MS) and the mechanisms underlying its origin are poorly understood. Our aim was to test whether fatigue in MS is associated with endocrine markers.

Methods We longitudinally studied 73 progressive MS patients. Fatigue was assessed at baseline and at 3, 6, 12 and 24 months using the Fatigue Severity Scale (FSS). Given the longitudinal design of our study, patients were labelled as sustained fatigued when FSS scores were 5.0 at all time points, and as non-fatigued when FSS scores were 5.0 at all time points. Serum levels of dehydroepiandrosterone (DHEA), its sulphated conjugate (DHEAS) and cortisol were measured at each time point.

Results Twenty-nine patients scored >5.0 in the FSS at all time points, and 9 patients (12.3%) scored 5.0 at all time points. Mean baseline levels of DHEAS and DHEA were lower in MS patients with sustained fatigue when compared to patients without fatigue (P=0.01 and P=0.03 respectively). Analysis of DHEAS and DHEA over time showed significantly lower hormone levels in patients with fatigue [F(1,31)=6.14, P=0.019 for DHEAS; F(1,32)= 6.63, P=0.015 for DHEA].

Conclusions Fatigue in progressive MS could be related to low serum levels of DHEA and DHEAS. Our results suggest that these hormones should be considered as biological markers of fatigue in MS patients and that hormone replacement may thus be tested as an option to treat fatigue in MS patients.

Key Words: dehydroepiandrosterone • DHEA • fatigue • MS • multiple sclerosis

Multiple Sclerosis, Vol. 12, No. 4, 487-494 (2006)
DOI: 10.1191/135248505ms1322oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J Sepulcre, J. Masdeu, J Goni, G Arrondo, N Velez de Mendizabal, B Bejarano, and P Villoslada Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways Multiple Sclerosis, March 1, 2009; 15(3): 337 - 344. [Abstract] [PDF]

				D. Kos, E. Kerckhofs, G. Nagels, M.B. D'hooghe, and S. Ilsbroukx Origin of Fatigue in Multiple Sclerosis: Review of the Literature Neurorehabil Neural Repair, February 1, 2008; 22(1): 91 - 100. [Abstract] [PDF]

				L. Krupp Editorial Multiple Sclerosis, August 1, 2006; 12(4): 367 - 368. [PDF]